Hematology has evolved from life-threatening diagnoses due to lack of treatments to the availability of many effective treatments for both genetic and immune driven hematology conditions. Current hematology dynamics the REACH team is tracking include:
- Real-world experience with groundbreaking gene editing and transfer therapies (e.g., Vertex/CRISPR Therapeutics’ Casgevy and bluebird bio’s Lyfgenia for Sickle Cell Disease; CSL Behring’s Hemgenix for Hemophilia B, BioMarin’s Roctavian for Hemophilia A)
- Novel therapies for immunohematology disorders
- Competitive dynamics in increasingly crowded hematology markets such as Hemophilia and Paroxysmal Nocturnal Hemoglobinuria (PNH)
Search Hematology diseases we cover